Virtus Investment Advisers, Inc. Incyte Corp Transaction History

Virtus Investment Advisers, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $141,228 - $176,823	2,134 New	2,134 $142,000
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $62,045 - $75,432	-747 Closed	0 $0
Q4 2017 Feb 26, 2018	SELL	$93.56 - $116.6 $268,517 - $334,642	-2,870 Reduced 79.35%	747 $71,000
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $338,406 - $421,742	3,617	3,617 $71,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.